Novavax, Inc. (NVAX) Receives Consensus Rating of “Hold” from Brokerages
Shares of Novavax, Inc. (NASDAQ:NVAX) have received a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $2.81.
Several equities analysts have recently commented on the stock. Zacks Investment Research cut shares of Novavax from a “buy” rating to a “hold” rating in a report on Tuesday, April 2nd. BidaskClub upgraded shares of Novavax from a “sell” rating to a “hold” rating in a report on Thursday, March 21st. Cantor Fitzgerald set a $1.00 price target on shares of Novavax and gave the company a “hold” rating in a report on Tuesday, March 19th. HC Wainwright boosted their price target on shares of Novavax from $2.00 to $2.13 and gave the company a “buy” rating in a report on Tuesday, March 19th. Finally, B. Riley reduced their price objective on shares of Novavax from $10.00 to $1.75 and set a “buy” rating for the company in a research note on Monday, March 4th.
In related news, Director Rachel K. King acquired 86,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were bought at an average price of $0.53 per share, for a total transaction of $45,580.00. Following the acquisition, the director now owns 42,000 shares in the company, valued at approximately $22,260. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.40% of the stock is currently owned by insiders.
NASDAQ:NVAX traded down $0.01 during mid-day trading on Monday, hitting $0.54. The company had a trading volume of 12,048 shares, compared to its average volume of 18,736,476. The firm has a market capitalization of $253.97 million, a PE ratio of -1.08 and a beta of 2.03. Novavax has a 1 year low of $0.49 and a 1 year high of $2.58.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). The firm had revenue of $6.13 million during the quarter, compared to the consensus estimate of $7.87 million. During the same quarter in the previous year, the business posted ($0.16) earnings per share. On average, research analysts predict that Novavax will post -0.39 EPS for the current fiscal year.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Further Reading: Using other technical indicators with support levels
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.